Pulse Biosciences (NASDAQ:PLSE – Get Free Report) and Autonomix Medical (NASDAQ:AMIX – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, profitability, analyst recommendations and dividends.
Institutional & Insider Ownership
77.0% of Pulse Biosciences shares are held by institutional investors. Comparatively, 10.8% of Autonomix Medical shares are held by institutional investors. 74.6% of Pulse Biosciences shares are held by company insiders. Comparatively, 6.2% of Autonomix Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Profitability
This table compares Pulse Biosciences and Autonomix Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pulse Biosciences | N/A | -67.70% | -58.89% |
| Autonomix Medical | N/A | -213.42% | -172.57% |
Risk and Volatility
Analyst Ratings
This is a summary of recent ratings and target prices for Pulse Biosciences and Autonomix Medical, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pulse Biosciences | 1 | 0 | 1 | 0 | 2.00 |
| Autonomix Medical | 1 | 1 | 1 | 0 | 2.00 |
Pulse Biosciences presently has a consensus price target of $22.00, indicating a potential upside of 51.20%. Autonomix Medical has a consensus price target of $5.00, indicating a potential upside of 960.90%. Given Autonomix Medical’s higher possible upside, analysts plainly believe Autonomix Medical is more favorable than Pulse Biosciences.
Earnings & Valuation
This table compares Pulse Biosciences and Autonomix Medical”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pulse Biosciences | N/A | N/A | -$53.58 million | ($1.13) | -12.88 |
| Autonomix Medical | N/A | N/A | -$11.41 million | ($4.65) | -0.10 |
Pulse Biosciences is trading at a lower price-to-earnings ratio than Autonomix Medical, indicating that it is currently the more affordable of the two stocks.
Summary
Pulse Biosciences beats Autonomix Medical on 6 of the 9 factors compared between the two stocks.
About Pulse Biosciences
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
About Autonomix Medical
Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
